Equities

Resverlogix Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Resverlogix Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.105
  • Today's Change0.00 / 0.00%
  • Shares traded12.67k
  • 1 Year change+110.00%
  • Beta1.0719
Data delayed at least 15 minutes, as of Feb 06 2026 19:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-9.73m
  • Incorporated2005
  • Employees18.00
  • Location
    Resverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
  • Phone+1 (403) 254-9252
  • Fax+1 (403) 254-9252
  • Websitehttps://www.resverlogix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirona Biochem Corp-16.37k-2.67m15.82m-----------0.0105-0.0105-0.00006-0.0134-0.0171--1.61---278.90-173.09---383.49-------1,405.28---5.73-----94.82-51.3728.52------
Numinus Wellness Inc5.33m-10.67m16.32m35.00------3.06-0.0366-0.04810.0175-0.00490.5827--3.41---116.67-77.90-231.32-88.0544.9631.24-200.23-325.94----3.02---82.02--51.75------
Neurothera Labs Inc0.00-209.09k16.98m----4.06-----0.0116-0.01160.000.04930.00-------19.28---21.28--------------0.00-------143.95------
Hemostemix Inc0.00-3.40m17.57m-----------0.03-0.030.00-0.01880.00-------453.77-579.31---------------6.01---------4.57------
Avicanna Inc25.50m-1.88m22.41m38.00--7.20--0.8789-0.0165-0.01650.22620.02641.222.8910.84---9.02-61.54-51.98-226.7251.9549.33-7.37-150.050.3804--0.00--51.62172.8858.62---44.27--
Principal Technologies Inc262.84k-4.32m29.19m--------111.07-0.1043-0.10720.0063-0.01260.2272--1.68---372.16---2,615.25-------1,637.81-----223.78-----44.22---162.24------
Resverlogix Corp0.00-9.73m30.19m18.00---------0.0343-0.03430.00-0.42470.00----0.00-91.25--------------0.0248-1.30--------54.39------
Thiogenesis Therapeutics Corp0.00-6.82m31.10m----14.44-----0.1439-0.14390.000.04150.00-------173.15---216.52--------------0.00------37.87------
Microbix Biosystems Inc18.59m-2.25m33.31m69.00--1.20--1.79-0.0161-0.01610.13440.19920.49231.126.44---5.953.86-6.484.3753.0255.92-12.086.375.17-2.230.196---26.8112.04-163.80---0.4115--
Briacell Therapeutics Corp0.00-39.36m41.55m22.00--0.7891-----73.05-73.050.007.260.00----0.00-246.96-63.88-359.42-70.71------------0.00-------449.14------
MustGrow Biologics Corp7.54m-6.37m44.00m0.00--14.16--5.84-0.1206-0.12060.14350.04941.455.4945.16---122.84-54.87-193.93-66.9514.51---84.52-341.261.25-103.310.1671---91.55---622.18------
Data as of Feb 06 2026. Currency figures normalised to Resverlogix Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.